Double unit cord blood transplantation

Double unit cord blood transplantation (DUCBT) has emerged as a successful strategy to improve engraftment and decrease transplant related mortality in adults and large children undergoing cord transplantation. In the vast majority of cases, one unit emerges as the sole source of long term hematopoiesis in the recipient following DUCBT. No factors have been identified that reliably predict which unit will emerge as the dominant unit, and limited studies have examined the mechanism underlying the observation. In a recent publication in Blood, we provide the first compelling data that effector CD8+ T cells play a critical role in the dominant unit actively rejecting the losing unit. Our findings provide an important first step in understanding the interactions following DUCBT, and provide insights that might be used to optimize graft versus leukemia effect and cord unit selection as well as better understand mechanisms of tolerance.

[1]  A. Scaradavou,et al.  Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. , 2010, Blood.

[2]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Bernstein,et al.  Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. , 2010, Blood.

[4]  J. Smits,et al.  Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies , 2009, Proceedings of the National Academy of Sciences.

[5]  J. Wagner,et al.  Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors. , 2009 .

[6]  J. Wagner,et al.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. , 2009, Blood.

[7]  W. Leisenring,et al.  Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  P. Quesenberry,et al.  Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  J. Wagner,et al.  Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. , 2009, Blood.

[10]  J. Klein,et al.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study , 2007, The Lancet.

[11]  J. Wagner,et al.  Double umbilical cord blood transplantation. , 2006, Current opinion in immunology.

[12]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[13]  K. Cornetta,et al.  Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.